SRR1445347
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.326
- OXIDATIVE_PHOSPHORYLATION+0.309
- KRAS_SIGNALING_DN+0.297
- SPERMATOGENESIS+0.289
- HEDGEHOG_SIGNALING+0.153
- BILE_ACID_METABOLISM+0.142
- ADIPOGENESIS+0.104
- FATTY_ACID_METABOLISM+0.091
- ESTROGEN_RESPONSE_LATE+0.078
- COAGULATION+0.074
Top 10 suppressed
- G2M_CHECKPOINT-0.485
- E2F_TARGETS-0.481
- IL6_JAK_STAT3_SIGNALING-0.478
- MYC_TARGETS_V1-0.461
- TNFA_SIGNALING_VIA_NFKB-0.436
- PROTEIN_SECRETION-0.419
- INTERFERON_ALPHA_RESPONSE-0.409
- INFLAMMATORY_RESPONSE-0.389
- UNFOLDED_PROTEIN_RESPONSE-0.385
- MTORC1_SIGNALING-0.383
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1486560 | GTEX | — | 0.959 |
| 2 | SRR1329377 | GTEX | — | 0.955 |
| 3 | SRR1440308 | GTEX | — | 0.955 |
| 4 | SRR598428 | GTEX | — | 0.951 |
| 5 | SRR1418923 | GTEX | — | 0.951 |
| 6 | SRR1354734 | GTEX | — | 0.949 |
| 7 | SRR1331335 | GTEX | — | 0.945 |
| 8 | SRR1414833 | GTEX | — | 0.944 |
| 9 | SRR1366433 | GTEX | — | 0.943 |
| 10 | SRR1465114 | GTEX | — | 0.942 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.326 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.309 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.297 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.289 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.153 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.142 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.104 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.091 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.078 | Idelalisib | — uncovered |
| COAGULATION | 0.074 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.070 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.068 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.014 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.012 | Inavolisib | — uncovered |